ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.71
-0.56%
US Tech 100
18,289.60
0.32%
S&P 500
5,307.01
-0.27%
US Dollar vs CAD
1.36905
0.36%
Bitcoin
69,010.83
-1.60%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Cellectis Nom Eo 05 (ALCLS)

  7. Cellectis Nom Eo 05 (ALCLS) News

ALCLS

Cellectis Nom Eo 05 (ALCLS)

Cellectis Nom Eo 05
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ALCLS
DateTimeSourceHeadlineSymbolCompany
05/16/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
05/16/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
05/06/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
05/06/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
05/06/20241:00AMGlobeNewswire Inc.Cellectis annonce la réalisation de l’investissement additionnel d’AstraZenecaEU:ALCLSCellectis Nom Eo 05
05/06/20241:00AMGlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
05/06/20241:00AMGlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
05/02/20243:30PMGlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
05/02/20243:30PMGlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
05/02/20243:30PMGlobeNewswire Inc.Cellectis nomme Arthur Stril directeur financier par intérimEU:ALCLSCellectis Nom Eo 05
04/29/20243:46PMGlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
04/29/20243:46PMGlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
04/29/20243:46PMGlobeNewswire Inc.Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 EU:ALCLSCellectis Nom Eo 05
04/22/20243:30PMGlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsEU:ALCLSCellectis Nom Eo 05
04/22/20243:30PMGlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsEU:ALCLSCellectis Nom Eo 05
04/22/20243:30PMGlobeNewswire Inc.Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs)EU:ALCLSCellectis Nom Eo 05
04/10/20243:30PMGlobeNewswire Inc.Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiéesEU:ALCLSCellectis Nom Eo 05
04/10/20243:30PMGlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsEU:ALCLSCellectis Nom Eo 05
04/10/20243:30PMGlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsEU:ALCLSCellectis Nom Eo 05
04/08/20243:30PMGlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingEU:ALCLSCellectis Nom Eo 05
04/08/20243:30PMGlobeNewswire Inc.Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCTEU:ALCLSCellectis Nom Eo 05
04/08/20243:30PMGlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingEU:ALCLSCellectis Nom Eo 05
04/04/20246:33PMGlobeNewswire Inc.CORRECTION : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
04/04/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
04/04/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
03/04/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
03/04/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
02/02/20243:30PMGlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
02/02/20243:30PMGlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
01/16/20243:30PMGlobeNewswire Inc.Cellectis annonce le tirage de la deuxième tranche de 15 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (la « BEI »)EU:ALCLSCellectis Nom Eo 05
 Showing the most relevant articles for your search:EU:ALCLS

Your Recent History

ASX
ALLKOP
LSE
86JX
Alandsbnkn 19
USOTC
TGMR
Troy Gold and Mineral (PK)
COIN
LEPENGBP
SUSHI
SEEDETH
Seed
LSE
33JT
Arkle 2bs
KUCN
TFUELBTC
Theta Fuel
COIN
DTCTBTC
COIN
VOLLETH
Volatility Protocol Token
NASDAQI
RXRESCPR
Benchmark Healthcare Rea...
BIT
P1TIN7
BNP Paribas Issuance
BOV
DEXP3
Dexxos Participacoes S.A ON
LSE
47UC
COIN
PERLUSD
Perlin
AMEX
HEET
Hartford Schroders ESG U...
UNSW
METETH
Metronome
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved